FORM
6-K
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
Report
of Foreign Issuer
Pursuant to Rule
13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of March 2022
Commission File
Number: 001-11960
AstraZeneca
PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge CB2
0AA
United
Kingdom
Indicate by check
mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check
mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number assigned to the
Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca
PLC
INDEX
TO EXHIBITS
1.
Update on CALLA Phase III trial of concurrent use
of Imfinzi
and chemoradiotherapy in locally advanced cervical
cancer
24
March 2022 07:00 GMT
Update
on CALLA Phase III trial of concurrent use of Imfinzi
and
chemoradiotherapy in locally advanced cervical cancer
The
CALLA Phase III trial for AstraZeneca’s Imfinzi (durvalumab) given concurrently
with chemoradiotherapy (CRT) did not achieve statistical
significance for the primary endpoint of improving progression-free
survival (PFS) versus CRT alone in the treatment of patients with
locally advanced cervical cancer.
Bradley
Monk, MD, FACOG, FACS, Professor at the University of Arizona
College of Medicine and principal investigator in the CALLA Phase
III trial, said: “While today’s results were not statistically
significant, they underscore the need for further evaluation of
novel therapeutic options and will inform future strategies to
improve treatment for patients with locally advanced cervical
cancer.”
Susan
Galbraith, Executive Vice President, Oncology R&D, AstraZeneca,
said: “CALLA tested a novel immunotherapy approach in locally
advanced cervical cancer, a devastating and complex disease where
many patients progress following available treatments. While the
results were not what we hoped for, insights from the trial will
advance our understanding and application of immunotherapy across
our broad clinical development programme, exploring the benefits of
Imfinzi in many tumour
types.”
The
safety and tolerability in this trial were consistent between the
two arms and no new unexpected safety findings were observed. The
data will be presented at a forthcoming medical
meeting.
Notes
Locally
advanced cervical cancer
Cervical cancer is
the eighth most common, and ninth most deadly, cancer worldwide,
with approximately 600,000 people diagnosed each year.1 Approximately 40-50%
of cervical cancer cases are diagnosed in the locally advanced
stage.2
Following current standard-of-care treatment, platinum-based
chemotherapy with radiation therapy, patients with locally advanced
cervical cancer face an approximately 40% chance of disease
recurrence and a five-year survival rate of about
65-70%.2,3
The standard-of-care treatment for these patients has not changed
in over two decades.4
CALLA
CALLA
is a randomised, multi-centre, double-blind, global Phase III trial
in which 770 patients with locally advanced cervical cancer were
treated with standard-of-care CRT in combination with either a
1,500mg fixed dose of Imfinzi or placebo every four weeks for
up to 24 cycles or until disease progression.
The
trial was conducted at 120 centres across 15 countries including in
the US, Europe, Latin America, Africa and Asia. The primary
endpoint was PFS and key secondary endpoints included overall
survival and safety and tolerability. For more information about
the trial, please visit Clinicaltrials.gov.
Imfinzi
Imfinzi (durvalumab) is a human
monoclonal antibody that binds to the PD-L1 protein and blocks the
interaction of PD-L1 with the PD-1 and CD80 proteins, countering
the tumour’s immune-evading tactics and releasing the inhibition of
immune responses.
Imfinzi is the only approved
immunotherapy in the curative-intent setting of unresectable, Stage
III non-small cell lung cancer (NSCLC) in patients whose disease
has not progressed after chemoradiotherapy, and is the global
standard of care in this setting based on the PACIFIC Phase III
trial.
Imfinzi is also approved in the US, EU,
Japan, China and many other countries around the world for the
treatment of extensive-stage small cell lung cancer based on the
CASPIAN Phase III trial.
In the past year,
Imfinzi has demonstrated
clinical benefit in multiple additional cancer settings with
positive Phase III trials in advanced biliary tract cancer
(TOPAZ-1), unresectable advanced liver cancer (HIMALAYA) and
metastatic NSCLC (POSEIDON).
As part
of a broad development programme, Imfinzi is being tested as a single
treatment and in combinations with other anti-cancer treatments for
patients with small cell lung cancer, NSCLC, bladder cancer,
several gastrointestinal cancers, ovarian cancer, endometrial
cancer and other solid tumours.
AstraZeneca
in immuno-oncology
Immunotherapy is a
therapeutic approach designed to stimulate the body’s immune system
to attack tumours. The Company’s Immuno-Oncology (IO) portfolio is
anchored in immunotherapies that have been designed to overcome
evasion of the anti-tumour immune response. AstraZeneca is invested
in using IO approaches that deliver long-term survival for new
groups of patients across tumour types.
The
Company is pursuing a comprehensive clinical trial programme that
includes Imfinzi as a
single treatment and in combination with tremelimumab and other
novel antibodies in multiple tumour types, stages of disease and
lines of treatment, and where relevant using the PD-L1 biomarker as
a decision-making tool to define the best potential treatment path
for a patient.
In
addition, the ability to combine the IO portfolio with radiation,
chemotherapy and targeted small molecules from across AstraZeneca’s
oncology pipeline, and from research partners, may provide new
treatment options across a broad range of tumours.
AstraZeneca
in oncology
AstraZeneca is
leading a revolution in oncology with the ambition to provide cures
for cancer in every form, following the science to understand
cancer and all its complexities to discover, develop and deliver
life-changing medicines to patients.
The
Company’s focus is on some of the most challenging cancers. It is
through persistent innovation that AstraZeneca has built one of the
most diverse portfolios and pipelines in the industry, with the
potential to catalyse changes in the practice of medicine and
transform the patient experience.
AstraZeneca has the
vision to redefine cancer care and, one day, eliminate cancer as a
cause of death.
AstraZeneca
AstraZeneca
(LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and
commercialisation of prescription medicines in Oncology, Rare
Diseases, and BioPharmaceuticals, including Cardiovascular, Renal
& Metabolism, and Respiratory & Immunology. Based in
Cambridge, UK, AstraZeneca operates in over 100 countries and its
innovative medicines are used by millions of patients worldwide.
Please visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For
details on how to contact the Investor Relations Team, please click
here. For Media
contacts, click here.
References
1.
World Health
Organization. Globocan 2020. World fact sheet. Available at:
https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf.
Accessed March 2022.
2.
Gennigens C,
et al. Optimal treatment in
locally advanced cervical cancer. Expert Rev Anticancer Ther.
2021;21(6):657-671.
3.
Espenel S,
et al. From IB2 to IIIB
locally advanced cervical cancers: report of a ten-year experience.
Radiat Oncol.
2018;13(16):1-11.
4.
Marth C,
et al. Cervical cancer:
ESMO Clinical Practice Guidelines for diagnosis, treatment and
follow-up. Annals of
Oncology 2017; 28 (4):IV72-IV83.
Adrian
Kemp
Company
Secretary
AstraZeneca
PLC
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Date:
24 March 2022
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Mai 2022 bis Jun 2022
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Jun 2021 bis Jun 2022
